AbCellera Phase 2 Data Drives a $200M Raise and Strong Q3 Beat

As seen on the 24/7 Wall St. homepage on November 9, 2026.

ABCL AbCellera Biologics
Q3 2026
EPS
-$0.13
est -$0.18 +26.8%
Revenue
$11M
est $6M +70.3%

Phase 2 data for hot flash antibody ABCL635 showed an 83% reduction in frequency versus 33% on placebo, enough to pull in an oversubscribed $200 million raise. Operating costs fell hard, narrowing the net loss to $40.8 million from $57.1 million a year ago. Twelve-week data lands in early 2027.

Continue ReadingShow less

AbCellera posted Q3 2026 revenue of $10.64 million, beating expectations, with nearly all of that coming from research fees. The GAAP loss per share of $0.13 also came in better than the estimate analysts had penciled in.

ABCL635, the company's NK3R-targeting antibody for vasomotor symptoms, delivered Phase 2 top-line data showing an 83% reduction in hot flash frequency at week four, compared with 33% for patients on placebo. That gap was wide enough to generate immediate investor interest and support a $200 million equity offering that closed oversubscribed.

On the cost side, both R&D and SG&A expenses fell sharply from a year ago, pulling the net loss down to $40.8 million from $57.1 million in Q3 2025. The narrowing loss reflects deliberate spending discipline, as the company simultaneously added three new pipeline programs: ABCL992, ABCL385, and ABCL646, all of which have entered IND-enabling activities.

Sponsored

The $200 million raise brought total available liquidity above $890 million, giving AbCellera a substantial runway to fund late-stage development. CEO Carl Hansen described the quarter as transformative, citing clinical execution and balance sheet expansion as the twin pillars of the result.

The next concrete catalyst is twelve-week efficacy and open-label extension data for ABCL635, expected in early 2027, followed by entry into late-stage development for menopausal vasomotor symptoms that same year. AbCellera also plans to start trials in 2027 targeting hot flashes caused by hormone-suppression therapies for breast and prostate cancer, an expansion that broadens the drug's addressable market.

Mentioned: ABCL